Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.

Van Nostrand D.

Thyroid. 2009 Dec;19(12):1381-91. doi: 10.1089/thy.2009.1611. Review.

PMID:
20001720
3.

Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S.

Thyroid. 2010 Mar;20(3):257-63. doi: 10.1089/thy.2009.0401.

PMID:
20187781
4.

Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.

Jarzab B, Handkiewicz-Junak D, Wloch J.

Endocr Relat Cancer. 2005 Dec;12(4):773-803. Review.

5.

Complications of radioactive iodine treatment of thyroid carcinoma.

Lee SL.

J Natl Compr Canc Netw. 2010 Nov;8(11):1277-86; quiz 1287. Review.

PMID:
21081784
6.

Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, Lange J, Perlemuter L, Askienazy S.

Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):974-81. Epub 2003 May 7.

PMID:
12734689
7.

The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB.

J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63. doi: 10.1210/jc.2012-1533. Epub 2012 May 25.

PMID:
22639291
8.

Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.

Rani D, Kaisar S, Awasare S, Kamaldeep, Abhyankar A, Basu S.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1767-80. doi: 10.1007/s00259-014-2737-3. Epub 2014 Apr 1.

PMID:
24687139
9.

Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.

Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, Metter D.

Endocr Relat Cancer. 2014;21(6):R473-84. doi: 10.1530/ERC-14-0286. Epub 2014 Oct 2. Review.

10.

The role of radioactive iodine in the treatment of well-differentiated thyroid cancer.

Weigel RJ, McDougall IR.

Surg Oncol Clin N Am. 2006 Jul;15(3):625-38. Review.

PMID:
16882501
11.

Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).

Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, Sack H.

Cancer. 1996 Jan 1;77(1):172-80.

12.

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.

Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC.

J Clin Endocrinol Metab. 2004 Aug;89(8):3668-76. Review.

PMID:
15292285
13.

Role of radioactive iodine for adjuvant therapy and treatment of metastases.

Jonklaas J.

J Natl Compr Canc Netw. 2007 Jul;5(6):631-40. Review.

PMID:
17623614
14.

Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.

Lim I, Kim SK, Hwang SS, Kim SW, Chung KW, Kang HS, Lee ES.

Ann Nucl Med. 2012 Dec;26(10):777-86. doi: 10.1007/s12149-012-0640-1. Epub 2012 Aug 7.

PMID:
22869417
15.

Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer.

Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW.

Ann Surg Oncol. 2012 Dec;19(13):4217-22. doi: 10.1245/s10434-012-2594-x. Epub 2012 Aug 11.

PMID:
23010732
16.

Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011. Epub 2011 Mar 15.

PMID:
21411300
17.

[Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].

Lind P, Igerc I, Kohlfürst S.

Wien Med Wochenschr. 2005 Oct;155(19-20):429-35. German.

PMID:
16424998
18.

[CME: Radioactive iodine therapy in thyroid cancer].

Steinert HC, Aberle S.

Praxis (Bern 1994). 2015 Nov 11;104(23):1235-43; quiz 1244-5. doi: 10.1024/1661-8157/a002189. Review. German.

PMID:
26558927
19.

Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following ¹³¹I treatment: a systematic review.

Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B.

Thyroid. 2010 Oct;20(10):1095-101. doi: 10.1089/thy.2009.0446. Review.

PMID:
20860418
20.

Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.

Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C.

J Nucl Med. 1996 Apr;37(4):598-605.

Supplemental Content

Support Center